Paper Details

  1. Home
  2. Paper Details

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Author: , Bar-OrAmit, CohenJeffrey A, ComiGiancarlo, CorrealeJorge, CoylePatricia K, CrossAnne H, GoodyearAlexandra, HauserStephen L, HäringDieter A, KakariekaAlgirdas, KapposLudwig, KerloeguenCecile, LeppertDavid, LiBingbing, MerschhemkeMartin, MontalbanXavier, PingiliRatnakar, RamanathanKrishnan, SelmajKrzysztof, TomicDavorka, WiendlHeinz, WilliRoman, de SezeJerome

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effects of ofatumumab and teriflunomide in patients with relapsing multiple sclerosis. Ofatumumab was found to be associated with lower annualized relapse rates, less disability worsening, and fewer gadolinium-enhancing lesions on MRI compared to teriflunomide. While both treatments had some side effects, ofatumumab showed more promising results in managing relapsing multiple sclerosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS: In ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1917246

データ提供：米国国立医学図書館（NLM）

A Tale of Two Therapies: Ofatumumab vs. Teriflunomide in Multiple Sclerosis

Multiple sclerosis (MS) is a complex and challenging neurological condition, and finding effective treatments remains a priority for researchers. This study investigates the relative efficacy of two medications, ofatumumab and teriflunomide, in managing relapsing MS. Researchers conducted two large-scale, double-blind, phase 3 trials, carefully comparing the effects of these medications on various MS-related outcomes. Like a desert traveler seeking different routes to reach a distant oasis, researchers explored the effectiveness of two distinct therapeutic pathways for managing MS.

Ofatumumab: A Promising Path to Reducing Relapses

The researchers found that ofatumumab, a monoclonal antibody that selectively depletes B cells, was associated with significantly lower annualized relapse rates compared to teriflunomide, an oral inhibitor of pyrimidine synthesis. Ofatumumab also showed a reduction in disability worsening and a favorable impact on MRI markers of disease activity. This study provides compelling evidence for the efficacy of ofatumumab in managing relapsing MS, offering a potentially effective treatment option for patients seeking to reduce relapses and slow disease progression.

New Hope for Managing MS: Choosing the Right Path

This study adds to the growing body of evidence supporting the use of ofatumumab in managing relapsing MS. The findings demonstrate its potential to reduce relapses, delay disability progression, and improve overall disease activity. This research offers a valuable tool for clinicians in choosing the most effective treatment options for their patients. As a researcher, I'm always excited by the potential of new therapies to improve the lives of those affected by debilitating conditions. This study underscores the importance of ongoing research to develop and refine treatments for MS, ultimately leading to better outcomes for patients.

Dr. Camel's Conclusion

This study demonstrates that ofatumumab is more effective than teriflunomide in reducing annualized relapse rates in patients with relapsing multiple sclerosis. The findings suggest that ofatumumab may offer a promising treatment option for managing this challenging neurological condition.

Date :
  1. Date Completed 2020-08-20
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

32757523

DOI: Digital Object Identifier

10.1056/NEJMoa1917246

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.